The complete amino acid sequence of a beta-galactoside-binding lectin from human placenta was determined at protein level. The lectin consists of 134 amino acids and its N-terminal alanine is blocked with acetate. The lectin shows about 50% similarity with chick 14K lectin, which was the first vertebrate beta-galactoside-binding lectin completely sequenced. Only 14 residues proved to be different from those of rat lung lectin, the sole mammalian lectin of which the complete sequence has been reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/oxfordjournals.jbchem.a122401 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Galectins and Liver Diseases.
Int J Mol Sci
January 2025
Departments of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kita-gun, Takamatsu 761-0793, Kagawa Prefecture, Japan.
Galectins are widely distributed throughout the animal kingdom, from marine sponges to mammals. Galectins are a family of soluble lectins that specifically recognize β-galactoside-containing glycans and are categorized into three subgroups based on the number and function of their carbohydrate recognition domains (CRDs). The interaction of galectins with specific ligands mediates a wide range of biological activities, depending on the cell type, tissue context, expression levels of individual galectin, and receptor involvement.
View Article and Find Full Text PDFmGBP2 engages Galectin-9 for immunity against Toxoplasma gondii.
PLoS One
January 2025
Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Guanylate binding proteins (GBPs) are large interferon-inducible GTPases, executing essential host defense activities against Toxoplasma gondii, an invasive intracellular apicomplexan protozoan parasite of global importance. T. gondii establishes a parasitophorous vacuole (PV) which shields the parasite from the host's intracellular defense mechanisms.
View Article and Find Full Text PDFMorphological and immunohistochemical analysis in encapsulated follicular variant papillary thyroid carcinoma, invasive follicular variant papillary thyroid carcinoma and a new entity: non-invasive follicular thyroid neoplasm with papillary nuclear feature.
Pol J Pathol
January 2025
Department of Pathology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey.
Thyroid cancers are the most common endocrine organ cancers. Encapsulated follicular variant papillary thyroid carcinomas (EFVPTC) are quite slow (indolent). Non-invasive follicular thyroid neoplasm with papillary nuclear feature (NIFTP) is a new entity identified as a result of studies in recent years.
View Article and Find Full Text PDFAssociation Between Serum Levels of Sestrin-2 and Galectin-3 and Atrial Remodelling in Patients with Atrial Fibrillation.
J Coll Physicians Surg Pak
January 2025
Department of Cardiovascular Medicine, Second People's Hospital of Anhui Province, Hefei, China.
Objective: To explore the prognostic significance of Sestrin-2 and Galectin-3 levels in atrial fibrillation complicated by left atrial remodelling, aiming to offer novel insights for prevention, treatment, and follow-up strategies.
Study Design: Analytical study. Place and Duration of the Study: Department of Cardiology, Second People's Hospital of Anhui Province, Hefei, China, from January 2021 to December 2023.
PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells.
J Transl Med
January 2025
Joint Research Center for Occupational Medicine and Health of IHM, School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Background: PRDX2 is significantly expressed in various cancers and is associated with the proliferation of tumor cells. Nonetheless, the precise mechanism of PRDX2 in tumor immunity remains incompletely understood. This study aims to investigate the impact of PRDX2, which is highly expressed in lung adenocarcinoma, on T cells in the tumor immune microenvironment, and its immune action target to promote the immune escape of lung cancer cells, to provide a theoretical basis for lung adenocarcinoma treatment with PRDX2 as the target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!